Search results for: Health Care Systems
Filter search results
Seminar Briefing: NHS Agency Staffing and the Impact of Recent Interventions
24 January 2018
…long lead time for training health care staff means that there can sometimes be a shortfall in available staff. This has made recruitment agencies and individual locum staff important suppliers…
Why are Mortality Rates Rising for Middle-Aged White Non-Hispanic Americans? Could it Happen in Europe? 24th Annual Lecture Publication
19 March 2018
Download OHE’s 24th Annual Lecture publication: Why are Mortality Rates Rising for Middle-Aged White Non-Hispanic Americans? Could it Happen in Europe? In June 2017, Professor Anne Case and Professor Sir…
Professor Graham Cookson Appointed OHE Director Designate
24 April 2018
…of Economic & Public Policy and Head of the Department of Health Care Management & Policy at University of Surrey. There he won major health research grants from the EU…
OHE’s In-house Publications Are Now Indexed by RePEc
8 May 2018
OHE is on RePEc: find publications from the Office of Health Economics in Research Papers in Economics. For many years, we’ve been publishing our work – free to read – on…
Should Drug Prices Differ by Indication? The Debate on Indication-based Pricing
11 May 2018
…that the price of a medicine should be linked in some way to the value it generates for patients and the health system is generally accepted. Yet, how can this…
A Critique of Hill et al. (2018) on Estimated Costs of Production for the WHO Essential Medicines List
19 May 2018
…reviews “Estimated costs of production and potential prices of medicines for the World Health Organization Essential Medicines List” (Hill et al., 2018) in which the authors argue for “greater transparency…
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
…impact of (i) incentives for R&D based on providing intellectual property (IP) rights protection; (ii) market competition; and (iii) other factors, including healthcare policies, on access to DAAs in Europe. …
Time to Tackle the Challenges around Combination Therapies for Cancer
29 March 2021
…improving clinical development to identify optimum treatment paradigms (such as treatment durations and stopping rules that optimise health benefits and minimise adverse effects and costs). This is important but challenging….
OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates
3 December 2021
…coming onto the market. Importantly, the CBO model cannot project the type of innovation that would be lost, the populations impacted, or the impact of policy change on population health. …